Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

2(40%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

60%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(1)

Other(1)

Detailed Status

Recruiting2

Suspended1

Completed1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 23 (60.0%)

Trials by Status

suspended120%

recruiting240%

completed120%

not_yet_recruiting120%

Recent Activity

2 active trials

Showing 5 of 5

recruitingphase_2

Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

NCT02878772

Clinical Trials (5)

Showing 5 of 5 trials

NCT07229664Phase 2

Vinpocetine in Patients With Parkinsonian Disease

Recruiting

NCT06635746Phase 1

Dose Escalation Study of Vinpocetine in Healthy Volunteers

Not Yet Recruiting

NCT02011971Phase 1

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

Suspended

NCT06441591Phase 2

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

Recruiting

NCT02878772Phase 2

Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5